{"product_id":"cancer-consult-expertise-in-clinical-practice-volume-2-9781119823124","title":"Cancer Consult Expertise in Clinical Practice","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003e\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003e\u003cp\u003eEditors Volume 2 xii\u003c\/p\u003e \u003cp\u003ePreface xiii\u003c\/p\u003e \u003cp\u003eAuthor Bios xv\u003c\/p\u003e \u003cp\u003eAcknowledgement xvii\u003c\/p\u003e \u003cp\u003e\u003cb\u003eVolume 1: Solid Tumors \u0026amp; Supportive Care\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eVolume 1 Editors:\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eSyed A. Abutalib, Maurie Markman, Al B. Benson III, and Hope S. Rugo\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 1 Acute Lymphoblastic Leukemia in Adults 1\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e1 Prognostic Markers and Models in Acute Lymphoblastic Leukemia 3\u003cbr\u003e\u003ci\u003eDieter Hoelzer\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e2 Acute Lymphoblastic Leukemia—Treatment and Outcomes in B-ALL 11\u003cbr\u003e\u003ci\u003eVijaya Raj Bhatt, Prajwal Dhakal, and Syed A. Abutalib\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e3 T Cell Acute Lymphoblastic Leukemia and Acute Lymphoblastic Lymphoma 27\u003cbr\u003e\u003ci\u003eSyed A. Abutalib and Daniel J. DeAngelo\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e4 Minimal Residual Disease in Acute Lymphoblastic Leukemia 51\u003cbr\u003e\u003ci\u003eCaner Saygin, Sarah Monick, and Wendy Stock\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e5 Hematopoietic Transplantation and Cellular Therapy in Acute Lymphoblastic Leukemia 63\u003cbr\u003e\u003ci\u003eYael Morgenstern, Netanel A. Horowitz, and Jacob M. Rowe\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 2 Acute Myeloid Leukemia in Adults 81\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e6 Prognosis in Acute Myeloid Leukemia: Beyond Cytogenetics 83\u003cbr\u003e\u003ci\u003eCaner Saygin and Lucy A. Godley\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e7 Young Adults with Acute Myeloid Leukemia 93\u003cbr\u003e\u003ci\u003eSangeetha Venugopal and Farhad Ravandi\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e8 Older Adults with Acute Myeloid Leukemia 103\u003cbr\u003e\u003ci\u003eMary-Elizabeth Percival and Elihu Estey\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e9 Acute Promyelocytic Leukemia 113\u003cbr\u003e\u003ci\u003eEytan M. Stein and Martin S. Tallman\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e10 Measurable Residual Disease in Acute Myeloid Leukemia 121\u003cbr\u003e\u003ci\u003eMarie Bill and Hans Beier Ommen\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e11 Hematopoietic Cell Transplantation and Cellular Therapy in Acute Myeloid Leukemia 133\u003cbr\u003e\u003ci\u003ePiyanuch Kongtim and Stefan O. Ciurea\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 3 Myelodysplastic Syndromes and Familial Myeloid Neoplasms 147\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e12 Diagnosis of Myelodysplastic Syndromes 149\u003cbr\u003e\u003ci\u003eJay Yang, Vijendra Singh, Ali Gabali, and Charles A. Schiffer\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e13 Treatment of Myelodysplastic Syndromes 165\u003cbr\u003e\u003ci\u003eRami S. Komrokji\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e14 Hematopoietic Cell Transplantation and Cellular Therapy in Myelodysplastic Syndromes 179\u003cbr\u003e\u003ci\u003eIbrahim Yakoub-Agha\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e15 Familial Myeloid Neoplasms—When to Suspect and What to Do? 191\u003cbr\u003e\u003ci\u003eRyan J. Stubbins, Amy M. Trottier , Simone Feurstein, and Lucy A. Godley\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 4 Myeloproliferative Neoplasms 211\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e16 Chronic Myeloid Leukemia: Chronic Phase Disease 213\u003cbr\u003e\u003ci\u003eJerald P. Radich\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e17 Chronic Myeloid Leukemia: Advance Phases of the Disease 221\u003cbr\u003e\u003ci\u003eMichael J. Mauro\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e18 Chronic Myeloid Leukemia: Treatment Safety During Reproductive Age and Pregnancy 229\u003cbr\u003e\u003ci\u003eMichael J. Mauro\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e19 Chronic Myeloid Leukemia: Cessation of Therapy 235\u003cbr\u003e\u003ci\u003eAnand A. Patel and Richard A. Larson\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e20 Hematopoietic Cell Transplantation in Chronic Myeloid Leukemia 243\u003cbr\u003e\u003ci\u003eJerald P. Radich\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e21 Polycythemia Vera 255\u003cbr\u003e\u003ci\u003ePrithviraj Bose and Srdan Verstovsek\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e22 Essential Thrombocythemia 265\u003cbr\u003e\u003ci\u003ePaola Guglielmelli and Alessandro Maria Vannucchi\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e23 Primary Myelofibrosis 275\u003cbr\u003e\u003ci\u003eDouglas Tremblay, Sangeetha Venugopal, John Mascarenhas, and Ruben Mesa\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e24 Hematopoietic Cell Transplantation and Cellular Therapy in Primary and Post ET\/PV Myelofibrosis 287\u003cbr\u003e\u003ci\u003eJerry Luo, Irum Khan, and Damiano Rondelli\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e25 Chronic Myelomonocytic Leukemia 305\u003cbr\u003e\u003ci\u003eMrinal M. Patnaik\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e26 Eosinophilic Myeloproliferative Disorders 315\u003cbr\u003e\u003ci\u003eJason Gotlib\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 5 Chronic Lymphocytic and Other Leukemias 331\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e27 Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma 333\u003cbr\u003e\u003ci\u003eJayastu Senapati, Nitin Jain, and Susan O'Brien\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e28 Hematopoietic Cell Transplantation and Cellular Therapy in Chronic Lymphocytic Leukemia 345\u003cbr\u003e\u003ci\u003eAjay Major, Michael R. Bishop, and Peter A. Riedell\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e29 Prolymphocytic Leukemia 357\u003cbr\u003e\u003ci\u003eDima El-Sharkawi and Claire Dearden\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e30 Hairy Cell Leukemia 371\u003cbr\u003e\u003ci\u003eJustin M. Watts and Martin S. Tallman\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 6 Hodgkin Lymphoma 385\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e31 Classic Hodgkin Lymphoma 387\u003cbr\u003e\u003ci\u003eChristopher R. D'Angelo, James O. Armitage, and Nancy L. Bartlett\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e32 Nodular Lymphocyte-Predominant Hodgkin Lymphoma 401\u003cbr\u003e\u003ci\u003eDennis A. Eichenauer\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e33 Hematopoietic Cell Transplantation and Cellular Therapy in Hodgkin Lymphoma 408\u003cbr\u003e\u003ci\u003eNarendranath Epperla, Alex F. Herrera, and Matthew Mei\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 7 Non-Hodgkin's Lymphomas 417\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e34 Pitfalls in the Diagnosis of Non-Hodgkin's Lymphomas 419\u003cbr\u003e\u003ci\u003eCarmen Barcena and Laurence de Leval\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e35 Follicular Lymphoma 435\u003cbr\u003e\u003ci\u003eDanielle Wallace, Nancy Torres, and Carla Casulo\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e36 Mantle Cell Lymphoma 447\u003cbr\u003e\u003ci\u003eChristina Poh and Stephen D. Smith\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e37 Marginal Zone Lymphoma 455\u003cbr\u003e\u003ci\u003eErin Mulvey, Wayne Tam, and Peter Martin\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e38 Hematopoietic Cell Transplantation and Cellular Therapy in Indolent Non-Hodgkin's Lymphomas 471\u003cbr\u003e\u003ci\u003eKarthik Nath and Craig S. Sauter\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e39 Diffuse Large B Cell Lymphoma 485\u003cbr\u003e\u003ci\u003eAlessia Castellino and Grzegorz S. Nowakowski\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e40 Hematopoietic Cell Transplantation and Cellular Therapy in Diffuse Large B Cell Lymphoma 499\u003cbr\u003e\u003ci\u003eShreya Desai, Syed Maaz Tariq, Arjun Patel, Istvan Redei, and Syed A. Abutalib\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e41 Primary Mediastinal Large B Cell Lymphoma 515\u003cbr\u003e\u003ci\u003eAlessandro Broccoli and Pier Luigi Zinzani\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e42 Double-Hit and Double-Expressor Lymphomas 525\u003cbr\u003e\u003ci\u003eDavid A. Russler-Germain and Brad S. Kahl\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e43 Transformed Lymphoma 539\u003cbr\u003e\u003ci\u003eFrederique St-Pierre and Jane N. Winter\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e44 Burkitt Lymphoma 555\u003cbr\u003e\u003ci\u003eMark Roschewski and Wyndham Wilson\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e45 Primary and Secondary CNS Lymphomas 563\u003cbr\u003e\u003ci\u003eLeon D. Kaulen, Nicholas A. Blondin, Fred H. Hochberg, and Joachim M. Baehring\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e46 HIV-Associated Lymphoma 579\u003cbr\u003e\u003ci\u003eElif Yilmaz and Kieron Dunleavy\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e47 Waldenström's Macroglobulinemia 589\u003cbr\u003e\u003ci\u003eMorie A. Gertz\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e48 Primary Cutaneous Lymphomas 599\u003cbr\u003e\u003ci\u003eNicholas A. Trum, Jasmine Zain, Steven T. Rosen, and Christiane Querfeld\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e49 Mycosis Fungoides and Sézary Syndrome 635\u003cbr\u003e\u003ci\u003eRobert Stuver, Alison Moskowitz, Sarah Noor, and Steven M. Horwitz\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e50 Peripheral T-Cell Lymphoma 647\u003cbr\u003e\u003ci\u003eAvyakta Kallam and James O. Armitage\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 8 Plasma Cell Neoplasms and Related Disorders 659\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e51 Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma 661\u003cbr\u003e\u003ci\u003eFrancesco Maura, Dickran Kazandjian, and Ola Landgren\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e52 Risk Stratification Including Measurable Residual Disease in Multiple Myeloma 673\u003cbr\u003e\u003ci\u003eCharalampos Charalampous and Shaji Kumar\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e53 Newly Diagnosed Multiple Myeloma: Transplant Eligible 687\u003cbr\u003e\u003ci\u003eSagar Lonial\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e54 Newly Diagnosed Multiple Myeloma: Transplant Ineligible 699\u003cbr\u003e\u003ci\u003eDaniele Derudas and Claudio Cerchione\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e55 Relapsed\/Refractory Multiple Myeloma 713\u003cbr\u003e\u003ci\u003eNeha Korde and Saad Z. Usmani\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e56 Light-chain (AL) Amyloidosis 727\u003cbr\u003e\u003ci\u003eVaishali Sanchorawala\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e57 Bispecific T Cell Engager and Cell Based Immune Therapy in Multiple Myeloma 739\u003cbr\u003e\u003ci\u003eMeera Mohan, Parameswaran Hari, and Saurabh Chhabra\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 9 Special Issues in Neoplastic Hematology and Cellular Therapy 751\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e58 Treatment of Lymphomas During Pregnancy 753\u003cbr\u003e\u003ci\u003eKieron Dunleavy, Emanuele Zucca, and Fedro A. Peccatori\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e59 Complications and Management of CAR T Cell Therapy 767\u003cbr\u003e\u003ci\u003eRadowan A. Elnair and Matthew A. Lunning\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e60 Acute Graft-versus-Host Disease 781\u003cbr\u003e\u003ci\u003eAaron Etra, Uroosa Ibrahim, Jacques Azzi, and John E. Levine\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e61 Chronic Graft-versus-Host Disease 793\u003cbr\u003e\u003ci\u003eAndrew Trunk and Daniel R. Couriel\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIndex 809\u003c\/p\u003e","brand":"John Wiley \u0026 Sons Inc","offers":[{"title":"Default Title","offer_id":49407163302231,"sku":"9781119823124","price":99.0,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9781119823124.jpg?v=1730498392","url":"https:\/\/bookcurl.com\/products\/cancer-consult-expertise-in-clinical-practice-volume-2-9781119823124","provider":"Book Curl","version":"1.0","type":"link"}